ArticleAntimicrobial agents and chemotherapy2012
An isoniazid analogue promotes Mycobacterium tuberculosis-nanoparticle interactions and enhances bacterial killing by macrophages.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Meta-Analysis of Drug Delivery Approaches for Treating Intracellular Infections.Pharmaceutical research · 2022Pooled it
- Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 againstPharmaceutics · 2022Article
- Article
- Inorganic and Polymeric Nanoparticles for Human Viral and Bacterial Infections Prevention and Treatment.Nanomaterials (Basel, Switzerland) · 2021Review
- Novel Assay Platform to Evaluate Intracellular Killing ofFrontiers in immunology · 2021Article
- Nanoantibiotics: Functions and Properties at the Nanoscale to Combat Antibiotic Resistance.Frontiers in chemistry · 2021Review
- Multi-functionalized nanocarriers targeting bacterial reservoirs to overcome challenges of multi drug-resistance.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020Review
- Heterogeneous Strategies to Eliminate Intracellular Bacterial Pathogens.Frontiers in microbiology · 2020Review
- Spray-Dried, Nanoencapsulated, Multi-Drug Anti-Tuberculosis Therapy Aimed at Once Weekly Administration for the Duration of Treatment.Nanomaterials (Basel, Switzerland) · 2019Article
- Nanodelivery strategies for the treatment of multidrug-resistant bacterial infections.Journal of interdisciplinary nanomedicine · 2018Review
- Antimycobacterial susceptibility evaluation of rifampicin and isoniazid benz-hydrazone in biodegradable polymeric nanoparticles againstInternational journal of nanomedicine · 2018Article
- Gallium nanoparticles facilitate phagosome maturation and inhibit growth of virulent Mycobacterium tuberculosis in macrophages.PloS one · 2017Article
- Polymeric nanoparticles in development for treatment of pulmonary infectious diseases.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2016Review
- Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoenabled drug delivery systems against tuberculosis (TB) are thought to control pathogen replication by targeting antibiotics to infected tissues and phagocytes. However, whether nanoparticle (NP)-based carriers directly interact with Mycobacterium tuberculosis and how such drug delivery systems induce intracellular bacterial killing by macrophages is not defined. In the present study, we demonstrated that a highly hydrophobic citral-derived isoniazid analogue, termed JVA, significantly increases nanoencapsulation and inhibits M. tuberculosis growth by enhancing intracellular drug bioavailability. Importantly, confocal and atomic force microscopy analyses revealed that JVA-NPs associate with both intracellular M. tuberculosis and cell-free bacteria, indicating that NPs directly interact with the bacterium. Taken together, these data reveal a nanotechnology-based strategy that promotes antibiotic targeting into replicating extra- and intracellular mycobacteria, which could actively enhance chemotherapy during active TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.